Sublingual buprenorphine: A feasible alternative for treating breakthrough chronic pain

Buprenorphine hydrochloride is a partial μ-receptor agonist, an oxidized low-density lipoprotein receptor-1 agonist, and a delta and kappa receptor antagonist. Buprenorphine is also used in combination with naloxone for reducing opioid dependence and for opioid substitution therapy. [...]SL buprenorphine is another alternative for treating BTP as it gets absorbed fast, has a rapid onset of action, and has a better adverse effect profile compared to other opioids.